Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Jazz Pharmaceuticals

Jazz Pharmaceuticals
2003 FOUNDED
PUBLIC STATUS
1K-5K EMPLOYEES
JAZZ STOCK SYMBOL
11 INVESTMENTS
$150.06 SHARE PRICE (As of Tuesday Closing)
Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, as well as Erwinaze for acute lymphoblastic leukemia, Defitelio for severe veno-occlusive disease after stem cell transplant, and Vyxeos for acute myeloid leukemia.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • Waterloo Exchange
  • Waterloo Road
  • Dublin
  • Ireland

+353 (01) 000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Jazz Pharmaceuticals’s full profile, request a free trial.

Jazz Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$113.52 - $153.03 $8.49B $151.34 $10.59 540K 56.6M

Jazz Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 8,138,934 8,007,415 9,199,632 8,287,549
Revenue 2,056,478 1,890,922 1,618,693 1,487,973
EBITDA 893,535 823,269 684,027 708,168
Net Income 608,845 447,098 487,848 396,831
Total Assets 5,527,850 5,203,491 5,123,672 4,800,227
Total Debt 1,769,315 1,596,412 1,581,038 2,029,625
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Jazz Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Jazz Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Jazz Pharmaceuticals Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alexion Formerly VC-backed Boston, MA 0000 000000&0
000000000 00000000 Formerly VC-backed Canton, MA 000 00000 000000 - 000 00000
000000000 00000000 Formerly VC-backed Tarrytown, NY 0000 00000 000000000 00 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

Jazz Pharmaceuticals Investments & Acquisitions (11)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 13-Aug-2019 000000000000000000 00000 Pharmaceuticals 000000 0000000 00
0000 000000 (00000 10-Jul-2019 000000000 00000 00 00000 Buildings and Property 000000 0000000 00
00000 24-Apr-2019 00000 00000 00 00.00 Monitoring Equipment 000 00000 00
0000000 0000000000 11-Jul-2016 000000000000000000 00.00 Pharmaceuticals 00000000 0000000-000000
Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) 05-Aug-2014 Corporate Asset Purchase 00000 Other Devices and Supplies
To view this company’s complete investment and acquisition history, request access »

Jazz Pharmaceuticals Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 000000 12-Jun-2012 000000000000000000 00000 Completed
  • 0000 0000000000000
Prialt 05-May-2010 Merger/Acquisition Completed
To view this company’s complete exits history, request access »

Jazz Pharmaceuticals Subsidiaries (2)

Company Name Industry Location Founded
Cavion Pharmaceuticals Charlottesville, VA 2002
0000000 Pharmaceuticals Villa Guardia, Italy 0000
To view this company’s complete subsidiary history, request access »

Jazz Pharmaceuticals Executive Team (31)

Name Title Board
Seat
Contact
Info
Bruce Cozadd Chief Executive Officer & Chairman
Daniel Swisher Jr. Chief Operating Officer & President
Heidi Manna Senior Vice President & Chief Human Resources Officer
Jed Black MD Senior Vice President, Sleep and CNS Medicine
Michael Miller Executive Vice President

23 Former Executives

You’re viewing 5 of 31 executives. Get the full list »

Jazz Pharmaceuticals Board Members (20)

Name Representing Role Since Contact
Info
Bruce Cozadd Jazz Pharmaceuticals Chief Executive Officer & Chairman 000 0000
Catherine Sohn Self Board Member 000 0000
Heather McSharry Jazz Pharmaceuticals Board Member 000 0000
Norbert Riedel Ph.D Self Board Member 000 0000
Patrick Enright Self Board Member 000 0000

11 Former Board Members

You’re viewing 5 of 20 board members. Get the full list »